<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034410</url>
  </required_header>
  <id_info>
    <org_study_id>AS1411-C-203</org_study_id>
    <nct_id>NCT01034410</nct_id>
  </id_info>
  <brief_title>A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antisoma Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antisoma Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine
      in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the response rate (CR + CRi) of AS1411 at 40 and 80mg/kg/day in combination with cytarabine therapy with the response rate (CR + CRi) of cytarabine therapy alone</measure>
    <time_frame>Dec 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare duration of remission, disease free survival and overall survival of AS1411 at 40 or 80mg/kg/day in combination with cytarabine therapy with that of cytarabine alone.</measure>
    <time_frame>Dec 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the time to hematological recovery of AS1411 at 40 or 80mg/kg/day in combination with cytarabine therapy with that of cytarabine alone.</measure>
    <time_frame>Dec 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the safety of AS1411 at 40 or 80mg/kg/day in combination with cytarabine therapy with that of cytarabine alone.</measure>
    <time_frame>Dec 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare a range of PD markers in patients administered AS1411 in combination with cytarabine therapy with the same PD markers in patients administered cytarabine therapy alone.</measure>
    <time_frame>Dec 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further define the PK of AS1411</measure>
    <time_frame>Dec 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cytarabine 2g/m2 bid Days 4-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS1411-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS1411-80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS1411</intervention_name>
    <description>AS1411 40mg/kg/day or AS1411 80mg/kg/day</description>
    <arm_group_label>AS1411-40</arm_group_label>
    <arm_group_label>AS1411-80</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 2g/m2 bid Days 4-7</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>AS1411-40</arm_group_label>
    <arm_group_label>AS1411-80</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AML as defined by the World Health Organization (WHO) classification
             (Vardiman 2009)

          -  Primary refractory AML (defined as a failure to achieve a CR or CRi after therapy with
             curative intent) or AML in first relapse

          -  ECOG Performance status 0, 1 or 2

          -  Age &gt; 18 and &lt; 70 years

          -  For patients presenting with primary refractory AML, &gt; 20% blasts on baseline bone
             marrow assessment

          -  For patients presenting with relapsed AML, &gt; 5% blasts on baseline bone marrow
             assessment

        Exclusion Criteria:

          -  An initial diagnosis of acute promyelocytic leukemia (as defined by
             French-American-British criteria (Bennett 1976))

          -  Secondary AML, defined as AML evolving from antecedent hematological disorder or prior
             exposure to leukemogenic therapy or agent

          -  Clinically active CNS leukemia

          -  Previously received a total cumulative dose of cytarabine &gt; 6g/m2 in the last 6 months

          -  Previously received &gt; 1 induction regimen (Defined as 1 or 2 cycles of a drug or a
             drug combination administered as remission induction therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Stuart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospial</name>
      <address>
        <city>Changhua City</city>
        <state>Changhua Country</state>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>February 1, 2011</last_update_submitted>
  <last_update_submitted_qc>February 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fredrik Erlandsson, MD</name_title>
    <organization>Antisoma</organization>
  </responsible_party>
  <keyword>AS1411</keyword>
  <keyword>AML</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>aptamer</keyword>
  <keyword>nucleolin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

